Sanofi SA (XSWX:SAN) Stock Price, Trades & News

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	0.42
Equity-to-Asset	0.56
Debt-to-Equity	0.29
Debt-to-EBITDA	1.63
Interest Coverage	15.33
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	1.55	Distress Grey Safe
Beneish M-Score	-2.45	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	5.7
	3-Year EBITDA Growth Rate	-1.8
	3-Year EPS without NRI Growth Rate	-2.9
	3-Year FCF Growth Rate	-4.2
	3-Year Book Growth Rate	-0.1
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	7.56
	Future 3-5Y Total Revenue Growth Rate Estimate	7.13

Momentum Rank

5/10

	Name	Current	Vs Industry		Vs History
	6-1 Month Momentum %	-5.98
	12-1 Month Momentum %	7.77

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.09
	Quick Ratio	0.73
	Cash Ratio	0.3
	Days Inventory	272.84
	Days Sales Outstanding	62.24
	Days Payable	205

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Dividend Growth Rate	5.6
	3-Year Average Share Buyback Ratio	1.4
	Shareholder Yield %	10.36

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	72.07
	Operating Margin %	20.54
	Net Margin %	16.72
	EBITDA Margin %	26.71
	FCF Margin %	15.43
	OCF Margin %	23
	ROE %	10.71
	ROA %	6.09
	ROIC %	7.04
	3-Year ROIIC %	-12.01
	ROC (Joel Greenblatt) %	49.6
	ROCE %	6.85
	Years of Profitability over Past 10-Year	10
	Moat Score	8
	Tariff Resilience Score	8

GF Value Rank

8/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	11.78
	Forward PE Ratio	9.53
	PE Ratio without NRI	11.99
	Shiller PE Ratio	12.98
	Price-to-Owner-Earnings	8.68
	PS Ratio	1.97
	PB Ratio	1.27
	Price-to-Tangible-Book	23.77
	Price-to-Free-Cash-Flow	12.77
	Price-to-Operating-Cash-Flow	8.57
	EV-to-EBIT	15.39
	EV-to-Forward-EBIT	10.07
	EV-to-EBITDA	8.39
	EV-to-Forward-EBITDA	8.29
	EV-to-Revenue	2.24
	EV-to-Forward-Revenue	2.09
	EV-to-FCF	14.51
	Price-to-GF-Value	0.7
	Price-to-Projected-FCF	0.75
	Price-to-Median-PS-Value	0.7
	Price-to-Graham-Number	3.56
	Earnings Yield (Greenblatt) %	6.5
	FCF Yield %	8.03
	Forward Rate of Return (Yacktman) %	2.07

GF Value™: CHF104.3

XSWX:SAN

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with SAN. Try a 7-Day Free Trial to check it out.

Sanofi SA Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Sanofi SA Stock Events

Financials Calendars

Event	Date	Price (CHF)
Third quarter earnings conference call for 2026	2026-10-30	In 124 days
Third quarter earnings results for 2026	2026-10-30	In 124 days
Second quarter earnings conference call for 2026	2026-07-30	In 32 days
Second quarter earnings results for 2026	2026-07-30	In 32 days
General meeting for 2026	2026-04-29	73.20 (+0.00%)
First quarter earnings conference call for 2026	2026-04-23 07:00	73.20 (+0.00%)
First quarter earnings results for 2026	2026-04-23	73.20 (+0.00%)
Annual report for 2025	2026-02-18	--
Fourth quarter earnings conference call for 2025	2026-01-29 08:30	--
Fourth quarter earnings results for 2025	2026-01-29	--

Show

Entries

Press Release

	Subject	Date
	Sanofi announces leadership evolution in Specialty Care Business Unit	2026-02-17
	EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi	2025-10-16
	Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US	2025-09-26
	Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®	2025-09-10
	New Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week	2025-08-26
	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY	2025-07-27
	BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study	2025-07-22
	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY	2025-07-22
	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY	2025-07-17
	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY	2025-07-12

10/Page

Articles on Sanofi SA

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.